From Diagnosis to Management: The Role of AI in the AMD Market
To fully grasp the dynamics of the Age-Related Macular Degeneration (AMD) Market, it is essential to understand its key segments. The market is primarily segmented by the type of disease: dry AMD and wet AMD. Dry AMD accounts for the vast majority of cases, but until recently, it had no approved treatments, making it a market of immense unmet need and future growth potential. The market for wet AMD, although less common, is the most mature and commercially successful segment due to the availability of highly effective anti-VEGF drug therapies. The treatment segment is also crucial. It includes drug therapies, which are the dominant force, particularly anti-VEGF injections for wet AMD. These drugs, such as Lucentis, Eylea, and Avastin, generate billions in revenue and form the backbone of the market. The segment also includes a growing pipeline of new gene therapies and sustained-release drugs. Other treatment segments include dietary supplements for dry AMD, as well as a smaller category for surgical and laser-based therapies. Finally, the market can be segmented by end-user, with hospitals and specialty eye clinics being the largest consumers of these products. Understanding these different segments is critical for companies looking to develop targeted strategies and for investors seeking to identify growth opportunities. For a comprehensive breakdown of these segments and their respective growth trajectories, you can find a thorough report on the Age-Related Macular Degeneration Market.